Jefferies maintains a buy rating on AstraZeneca, expecting detailed data on its lung drug tozorakimab in September to compensate for a recent heart trial failure. The failed CARDIO-TTRansform study cut $4 billion from forecasts, but Jefferies believes tozorakimab, targeting IL-33 for chronic obstructive pulmonary disease, could deliver peak sales over $5 billion by 2030. The drug may benefit a broader patient group than existing treatments, potentially reducing flare-ups by 30% in former smokers. AstraZeneca faces competition but is seen as having strong commercial potential in this category.
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
Jefferies maintains a buy rating on AstraZeneca, highlighting that detailed data on its lung drug tozorakimab, due on 8 September, could offset the impact of a failed heart trial. The lung drug targets IL-33, potentially benefiting a broader COPD pat...
